[go: up one dir, main page]

AR117626A1 - COMPOSICIÓN QUE COMPRENDE INHIBIDOR DE LA a-1 PROTEINASA ALTAMENTE CONCENTRADO Y PROCEDIMIENTO PARA LA OBTENCIÓN DE LA MISMA - Google Patents

COMPOSICIÓN QUE COMPRENDE INHIBIDOR DE LA a-1 PROTEINASA ALTAMENTE CONCENTRADO Y PROCEDIMIENTO PARA LA OBTENCIÓN DE LA MISMA

Info

Publication number
AR117626A1
AR117626A1 ARP190102127A ARP190102127A AR117626A1 AR 117626 A1 AR117626 A1 AR 117626A1 AR P190102127 A ARP190102127 A AR P190102127A AR P190102127 A ARP190102127 A AR P190102127A AR 117626 A1 AR117626 A1 AR 117626A1
Authority
AR
Argentina
Prior art keywords
highly concentrated
proteinase inhibitor
procedure
obtaining
same
Prior art date
Application number
ARP190102127A
Other languages
English (en)
Inventor
Kelly Glancy
Michelle Speter
Kevin Wee
Thomas P Zimmerman
Eric Allgaier
Anthony Klos
Charles Miller
James Rebbeor
Original Assignee
Grifols Worldwide Operations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Worldwide Operations Ltd filed Critical Grifols Worldwide Operations Ltd
Publication of AR117626A1 publication Critical patent/AR117626A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Las composiciones incluyen inhibidor de la a-1 proteinasa (A1PI) altamente concentrado en una concentración superior o igual a 100 mg/ml. Las composiciones farmacéuticas se pueden preparar a partir de estas composiciones. Las composiciones farmacéuticas pueden ser adecuadas para la administración subcutánea. Las soluciones de A1PI altamente concentrado se pueden obtener mediante filtración tangencial sin recirculación “single pass” (SPTFF).
ARP190102127A 2018-08-02 2019-07-29 COMPOSICIÓN QUE COMPRENDE INHIBIDOR DE LA a-1 PROTEINASA ALTAMENTE CONCENTRADO Y PROCEDIMIENTO PARA LA OBTENCIÓN DE LA MISMA AR117626A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862713673P 2018-08-02 2018-08-02

Publications (1)

Publication Number Publication Date
AR117626A1 true AR117626A1 (es) 2021-08-18

Family

ID=67439017

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102127A AR117626A1 (es) 2018-08-02 2019-07-29 COMPOSICIÓN QUE COMPRENDE INHIBIDOR DE LA a-1 PROTEINASA ALTAMENTE CONCENTRADO Y PROCEDIMIENTO PARA LA OBTENCIÓN DE LA MISMA

Country Status (15)

Country Link
US (3) US11253578B2 (es)
EP (1) EP3632412A1 (es)
JP (2) JP7458717B2 (es)
KR (1) KR20200015409A (es)
CN (1) CN110787297B (es)
AR (1) AR117626A1 (es)
AU (1) AU2019204927B2 (es)
BR (1) BR102019014292A2 (es)
CA (1) CA3049584A1 (es)
CL (1) CL2019002131A1 (es)
IL (1) IL267923B2 (es)
MX (2) MX2024006655A (es)
SG (1) SG10201906599VA (es)
TW (1) TWI833778B (es)
UY (1) UY38315A (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL267923B2 (en) 2018-08-02 2023-06-01 Grifols Worldwide Operations Ltd The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it
CN115135667A (zh) 2020-02-25 2022-09-30 基立福环球运营有限公司 获得α-1蛋白酶抑制剂的方法
WO2024165043A1 (en) * 2023-02-08 2024-08-15 Beigene Switzerland Gmbh Preparation methods for a highly concentrated pd1 antibody solution by applying single-pass tangential flow filtration (sptff)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616693A (en) 1996-07-01 1997-04-01 Alpha Therapeutic Corporation Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
US6462180B1 (en) 1999-11-24 2002-10-08 Bayer Corporation Method of preparing α-1 proteinase inhibitor
ES2332402T5 (es) 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
DE60130791T2 (de) 2000-12-27 2008-07-17 Ares Trading S.A. Amphiphile lipid-nanopartikel zur peptid- und/oder proteininkorporation
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
NZ554885A (en) 2002-12-31 2009-07-31 Altus Pharmaceuticals Inc Complexes of hgh crystals and protamine polymers
SI1664123T2 (sl) 2003-09-22 2012-03-30 Kamada Ltd Priprava inhibitorja alfa proteinaze v velikem merilu in njegova uporaba
JP2007534633A (ja) 2003-11-10 2007-11-29 アライバ−プロメティック インコーポレイティド ヒト・アルファ１−抗トリプシン製剤
WO2005048985A2 (en) 2003-11-14 2005-06-02 Baxter International Inc. Alpha 1-antitrypsin compositions and treatment methods using such compositions
RU2268736C1 (ru) 2004-06-17 2006-01-27 Общество с ограниченной ответственностью "БиоГениус" Способ получения альфа-1-антитрипсина и продукт для использования в медицине
US7384549B2 (en) 2005-12-29 2008-06-10 Spf Innovations, Llc Method and apparatus for the filtration of biological solutions
US20110002909A1 (en) * 2007-11-02 2011-01-06 Vikram Arora Method, composition, and article of manufacture for providing alpha-1 antitrypsin
US20110237781A1 (en) 2008-07-18 2011-09-29 Talecris Biotherapeutics, Inc. Method of preparing alpha-1 proteinase inhibitor
ES2679819T3 (es) 2009-11-03 2018-08-31 Grifols Therapeutics Inc. Composición, método y kit para inhibidor de alfa-1 proteinasa
CA3107288A1 (en) * 2011-06-08 2012-12-13 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mrna delivery
EP2682168A1 (en) 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
CN103788209B (zh) * 2012-10-29 2016-02-24 广东双林生物制药有限公司 一种α1-蛋白酶抑制剂的制备方法
WO2015195453A2 (en) * 2014-06-16 2015-12-23 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
US20170312282A1 (en) * 2016-04-28 2017-11-02 The Board Of Trustees Of The Leland Stanford Junior University Tyrosine kinase inhibitor formulations for the treatment of mast cell-mediated inflammatory diseases and methods of use thereof
IL267520B2 (en) * 2016-12-22 2023-09-01 Kamada Ltd Dry powder composition of alpha-1 antitrypsin
IL267923B2 (en) 2018-08-02 2023-06-01 Grifols Worldwide Operations Ltd The composition containing the most concentrated alpha-1 type protein inhibitor and a method for obtaining it

Also Published As

Publication number Publication date
CA3049584A1 (en) 2020-02-02
CN110787297A (zh) 2020-02-14
US12144849B2 (en) 2024-11-19
CN110787297B (zh) 2023-08-18
IL267923A (en) 2020-02-27
JP2020019765A (ja) 2020-02-06
BR102019014292A2 (pt) 2020-02-18
AU2019204927B2 (en) 2025-12-11
US11253578B2 (en) 2022-02-22
US20200038494A1 (en) 2020-02-06
CL2019002131A1 (es) 2020-03-20
US20220000992A1 (en) 2022-01-06
US20230277636A1 (en) 2023-09-07
IL267923B2 (en) 2023-06-01
UY38315A (es) 2020-02-28
KR20200015409A (ko) 2020-02-12
US11701412B2 (en) 2023-07-18
AU2019204927A1 (en) 2020-02-20
MX2019008968A (es) 2020-02-03
JP2024040213A (ja) 2024-03-25
JP7458717B2 (ja) 2024-04-01
SG10201906599VA (en) 2020-03-30
MX2024006655A (es) 2024-06-19
TWI833778B (zh) 2024-03-01
EP3632412A1 (en) 2020-04-08
TW202019945A (zh) 2020-06-01

Similar Documents

Publication Publication Date Title
SA519402405B1 (ar) مركبات مثبط فيروس نقص المناعة البشري
ECSP099792A (es) Nuevos peptidos inhibidores de la replicacion del virus de hepatitis c
WO2019191229A8 (en) Compounds for treating huntington's disease
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
AR055095A1 (es) Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c
EA201171216A1 (ru) Фенилацетат l-орнитина и способы его получения
UY37998A (es) Agentes antivirales contra la hepatitis b
EA200501268A1 (ru) Ингибирующие вич 1,2,4-триазины
AR117626A1 (es) COMPOSICIÓN QUE COMPRENDE INHIBIDOR DE LA a-1 PROTEINASA ALTAMENTE CONCENTRADO Y PROCEDIMIENTO PARA LA OBTENCIÓN DE LA MISMA
CY1126067T1 (el) Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30)
MX2024006689A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
WO2020044119A3 (en) Oral formulations of lavender and cannabinoids
MX2024010373A (es) Metodos y composiciones para el tratamiento de la hipertension pulmonar.
MX2008013017A (es) Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
CL2021001629A1 (es) Compuestos de halo-alilamina y uso de los mismos
MX2023013515A (es) Inhibidores de la interaccion de menina-mll.
CO2022015428A2 (es) Compuesto de oxofenilarsina deuterada y uso del mismo
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
UY28282A1 (es) Mediadores peptidicos del trasporte inverso de colesterol para el tratamiento de hipercolesterolemia
MX2021012392A (es) Compuestos, composiciones y metodos.
MX2024009773A (es) Composicion farmaceutica que comprende derivados de difenildiazol y metodos de uso.
EA202192422A1 (ru) Человеческий сывороточный альбумин в составах
MX2021014555A (es) Composiciones y métodos de tratamiento de la retinopatía.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal